Sildenafil

Sildenafil is an orally active inhibitor of phosphodiesterase type 5 (PDE5) that Pfizer scientists first synthesized at their research site in Sandwich, England, while searching for treatments for angina and high blood pressure ^[1]. During early trials the compound proved disappointing for its intended cardiovascular purpose but produced a striking effect on penile erections, and the program was redirected toward erectile dysfunction ^[1]. The United States Food and Drug Administration approved it in 1998, making it the first oral therapy for the condition and reshaping how erectile dysfunction was viewed and treated ^[1].

In erectile dysfunction, pooled analyses of randomized trials show that sildenafil markedly raises the likelihood of successful intercourse compared with placebo and works across a range of patient groups, including men with diabetes ^[2]. It has become a benchmark against which newer PDE5 inhibitors are measured; head-to-head comparisons with the longer-acting tadalafil find broadly similar efficacy and safety, with differences mainly in duration and side-effect pattern ^[3]. Under the brand name Revatio, sildenafil is separately used to lower pressure in the pulmonary arteries in pulmonary arterial hypertension ^[1].

Sildenafil is a prescription medicine in most countries, and generic versions have been widely available since patents began expiring in the 2010s ^[1]. It is supplied chiefly as oral tablets, with additional formulations used in specialist settings ^[2]. Its shift from a niche cardiovascular candidate to a globally recognized brand is often cited as a classic example of drug repurposing through serendipity ^[1].

The drug is generally well tolerated, and in controlled trials it was not linked to serious cardiovascular events at approved use, although it is contraindicated together with nitrate medications because of the risk of dangerous falls in blood pressure ^[2]. Its typical adverse effects follow from its blood-vessel-relaxing action ^[3].

Sildenafil is a PDE5 inhibitor whose common effects include headache, flushing, nasal congestion, indigestion, and transient visual color changes. It is contraindicated with nitrates and with riociguat because the combination can cause dangerous drops in blood pressure, and caution is needed with alpha-blockers and in significant cardiovascular disease. Rare but serious risks include priapism, a prolonged erection requiring emergency care, sudden vision loss (NAION), and sudden hearing loss.

Sildenafil has a well-documented pharmacodynamic interaction with nitrates, including sublingual nitroglycerin and long-acting nitrates; co-administration causes severe additive vasodilation and life-threatening hypotension ^[5]. This interaction is contraindicated in clinical practice. Sildenafil is metabolized by CYP3A4, creating a pharmacokinetic interaction with CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, and clarithromycin; these inhibitors increase sildenafil exposure and systemic side effects, and some experts recommend dose reduction ^[6].

The magnitude of sildenafil level increases with CYP3A4 inhibitors can be substantial; grapefruit juice also inhibits CYP3A4 metabolism. Co-administration with alpha-blockers used for hypertension or prostate symptoms requires monitoring for additive blood pressure reduction, though this is less well-characterized than the nitrate interaction. Most other common medications do not have documented significant interactions with sildenafil, but the nitrate contraindication is absolute and well-established across clinical guidelines.

Checking a whole stack? Run it through interactions + stacks.

Sildenafil was discovered by medicinal chemists at Pfizer's research laboratories in Sandwich, Kent, England, during the early 1990s, where it carried the internal code UK-92480 and was developed as a candidate for angina and hypertension by inhibiting phosphodiesterase type 5. Clinical studies for heart conditions proved underwhelming, but investigators noted a striking and consistent report from male volunteers of improved erections, prompting Pfizer to redirect the compound toward erectile dysfunction.

The company patented the molecule and its use, and on 27 March 1998 the United States Food and Drug Administration approved it as Viagra, the first oral treatment for erectile dysfunction. The launch was a commercial and cultural landmark, rapidly making the drug one of the most recognizable pharmaceuticals in the world. In 2005 the same molecule was approved under the brand Revatio for pulmonary arterial hypertension, reflecting the vasodilatory action it shares across vascular beds. The serendipitous path from a failed cardiovascular drug to a first-in-class therapy is now a frequently cited example of pharmacological repurposing.

Sildenafil enjoys an exceptionally strong reputation built on decades of use, a large body of controlled trial evidence, and familiarity among clinicians and patients worldwide. It reliably improves erectile function in a broad range of men, including those with diabetes and cardiovascular risk factors, and its on-demand dosing gives users a predictable window of effect. Its safety profile is well characterized after enormous real-world exposure, with common effects such as headache, flushing, and nasal congestion generally mild and transient.

In pulmonary arterial hypertension it earned a distinct clinical role by improving exercise capacity and hemodynamics. Its main limitations are honest and well understood; it requires sexual stimulation to work, must not be combined with nitrates, and does not address the psychological or hormonal causes of dysfunction. Even so, it remains a benchmark against which newer agents are measured.